ADAMI Silvano |
Bisphosphonates
treatment in infants with severe osteogenesis imperfecta. |
P
04 |
ADAMI Silvano |
Cyclic administration of
intravenous neridronate has positive effects on morbidity in growing
patients with osteogenesis imperfecta. |
P
05 |
AFIFI Amal |
A diagnostic assay for col1a1
expression levels in osteogenesis imperfecta patients |
P
01 |
ALLEN Danny |
Development of rnai as a
mutation independent gene therapy for osteogenesis imperfecta |
P
02 |
AMAKO Masatoshi |
Functional analysis of upper-limb
deformities in osteogenesis imperfecta |
P
03 |
ANNEQUIN Daniel |
Osteogenesis imperfecta,
pain assesment and treatment |
P
58 |
ANTICEVIC Darko |
Our experience in bisphosphonate
therapy for osteogenesis imperfecta |
P
28 |
ANTICEVIC Darko |
Bone markers reveal decreased
collagen type i synthesis and change in bone turnover during bisphosphonate
treatment in osteogenesis imperfecta |
P
33 |
ANTONIAZZI Franco |
Bisphosphonates treatment
in infants with severe osteogenesis imperfecta. |
P
04 |
ANTONIAZZI Franco |
Cyclic administration of
intravenous neridronate has positive effects on morbidity in growing
patients with osteogenesis imperfecta. |
P
05 |
ARABI Asma |
Pamidronate in children
with osteogenesis imperfecta |
P
19 |
ARISKOSKI Pekka |
Assessment of indices of
dual-energy x-ray absorptiometry and bone metabolic markers during
the first year of intravenous pamidronate treatment in children with
moderate-severe osteogenesis imperfecta |
P
06 |
ÅSTRÖM Eva
|
Beneficial effects of long
term intravenous apd treatment of children and adolescents with osteogenesis
imperfecta (OI) |
P
07 |
AULT Jennifer
|
Cyclic intravenous pamidronate
therapy for osteogenesis imperfecta |
P
52 |
AVIRAM-GOLDRING Ayala |
Osteogenesis imperfecta
and type 2 diabetes mellitus (mody) in two siblings |
P
21 |
AWADA-MADAYAN R. |
Preventive effect of fluoride
topics on crown abrasion of decidual teeth in dentinogenesis imperfecta |
P
25 |
BARD Rachel |
Use of occupational therapy
and psychomotricity to approach a child with O.I |
P
08 |
BARIC Ivo |
Bone markers reveal decreased
collagen type i synthesis and change in bone turnover during bisphosphonate
treatment in osteogenesis imperfecta |
P
33 |
BARISIC Ingeborg |
Our experience in bisphosphonate
therapy for osteogenesis imperfecta |
P
28 |
BARISIC Ingeborg |
Bone markers reveal decreased
collagen type I synthesis and change in bone turnover during bisphosphonate
treatment in osteogenesis imperfecta |
P
33 |
BARNAT Sonia |
Use of occupational therapy
and psychomotricity to approach a child with O.I |
P
08 |
BEEK Erik |
Osteogenesis imperfecta
in childhood : mr imaging of basilar impression -a follow up study |
P
30 |
BERGWITZ Clemens |
Making brittle bones better:
lessons from the brittle (brtl) mouse model for osteogenesis imperfecta
in post-pubertal adaptation of the oi skeleton. |
S
09 |
BERKENSTADT Michal |
Osteogenesis imperfecta
and type 2 diabetes mellitus (mody) in two siblings |
P
21 |
BERNARD Jean-Claude |
Use of occupational therapy
and psychomotricity to approach a child with O.I |
P
08 |
BERTAGNOLLI Elisabetta |
Bisphosphonates treatment
in infants with severe osteogenesis imperfecta |
P
04 |
BERTAGNOLLI Elisabetta |
Cyclic administration of
intravenous neridronate has positive effects on morbidity in growing
patients with osteogenesis imperfecta |
P
05 |
BISHOP Nicholas J. |
A diagnostic assay for col1a1
expression levels in osteogenesis imperfecta patients |
P
01 |
BISHOP Nicholas J. |
Assessment of indices of
dual-energy x-ray absorptiometry and bone metabolic markers during
the first year of intravenous pamidronate treatment in children with
moderate-severe osteogenesis imperfecta |
P
06 |
BOHNE Wolf |
Col1a2 mutation (g676v)
associated with osteogenesis imperfecta type IV b |
P
48 |
BOUCLON E. |
Preventive effect of fluoride
topics on crown abrasion of decidual teeth in dentinogenesis imperfecta |
P
25 |
BRIODY Julie |
Cyclic intravenous pamidronate
therapy for osteogenesis imperfecta |
P
52 |
BROCHET A. |
Le pied au cours de l’osteogenese
imparfaite : résultats préliminaires d’une enquête
anonyme |
P
56 |
BRONSTEIN Corinne |
Coagulation screening tests
in 35 children with osteogenesis imperfecta (OI) |
P
17 |
BYERS Peter H. |
Contemporary approaches
to the laboratory diagnosis of oi |
S
01 |
BYERS Peter H. |
Updated regional model of
a2(I) genotype-phenotype relationship in oi reveals alignment of lethal
clusters with proteoglycan binding regions of collagen |
P
43 |
BYERS Peter H. |
Four proa2(I) c-propeptide
defects hinder procollagen assembly and result in osteogenesis imperfecta
type IV |
P
45 |
BYERS Peter H. |
Biochemical testing for
osteogenesis imperfecta : a reluctant visitor to the U.S. Courtroom
|
P
47 |
BYERS Peter H. |
Analysis of the procollagen
type 1 genes in the israeliosteogenesis imperfecta patients |
P
51 |
CABRAL Wayne A. |
Two unaffected women who
are mosaics for col1a1 mutations causing type III and iv oi have a
high percent of mutant bone cells: implications for cell/gene therapy
|
P
09 |
CABRAL Wayne A. |
Type I collagen triplet
duplication mutation in lethal oi shifts register of ?-chains throughout
the helix, and disrupts incorporation of mutant helices into fibrils
and ecm |
P
10 |
CABRAL Wayne A. |
Updated regional model of
a2(I) genotype-phenotype relationship in oi reveals alignment of lethal
clusters with proteoglycan binding regions of collagen |
P
43 |
CABRAL Wayne A. |
Structure, stability and
interactions of type i collagen with gly349-cys substitution in a1(I)
chain in a murine osteogenesis imperfecta model |
P
37 |
CADILHAC C. |
Long term spinal fusion
in osteogenesis imperfecta patients. |
P
57 |
CADILHAC C. |
Principal complications
in limb surgery of osteogenesis imperfecta |
P
18 |
CAHUZAC Jean Philippe |
Identification of a missense
mutation of gnas1 by the protein nucleic acid (pna) method in a patient
with mc cune albright syndrome |
P
24 |
CARIVEN Clotilde |
Identification of a missense
mutation of gnas1 by the protein nucleic acid (pna) method in a patient
with mc cune albright syndrome |
P
24 |
CHAP Hugues |
Identification of a missense
mutation of gnas1 by the protein nucleic acid (pna) method in a patient
with mc cune albright syndrome |
P
24 |
CHASTAN Bernard |
Osteogenesis imperfecta
early rehabilitation : why ? How ? |
P
27 |
CHEN Diana |
Four proa2(I) c-propeptide
defects hinder procollagen assembly and result in osteogenesis imperfecta
type IV |
P
45 |
CHERNOFF Edith |
Interim data analysis from
a controlled trial of pamidronate in children with types III and IV
OI |
P
42 |
CLARK Christine |
Development of a potty chair
for children with osteogenesis imperfecta |
P
11 |
CLARK Christine |
Osteogenesis imperfecta
- a complex multi-system disorder requiring a multi-disciplinary approach |
P
12 |
CLARK Christine |
A standardised tool to measure
and describe scleral colour in osteogenesis imperfecta. |
P
59 |
CLARK Christine |
A survey of acute and chronic
pain in children with osteogenesis imperfecta. |
P
60 |
CLARK Christine |
Development of a clinical
research database on O.I. – lessons learnt along the way |
P
61 |
CLARK Christine |
Use of community health
services by people affected by osteogenesis imperfecta |
P
62 |
COLE William |
Molecular basis for OI |
S
02 |
COUCKE Paul |
Total absence of the a2(I)
chain due to a homozygous col1a2 mutation in a patient with an eds-like
phenotype |
P
13 |
COUDERC Rémy |
Effect of pamidronate administration
on markers of bone turnover in children with osteogenesis imperfecta |
P
49 |
COWELL Chris |
Cyclic intravenous pamidronate
therapy for osteogenesis imperfecta |
P
52 |
DALGLEISH Raymond |
The OI mutation database |
S
03 |
DALTON Ann |
A diagnostic assay for col1a1
expression levels in osteogenesis imperfecta patients |
P
01 |
DE ALMEIDA Salomé |
Total absence of the a2(I)
chain due to a homozygous col1a2 mutation in a patient with an eds-like
phenotype |
P
13 |
DE CARMOY Roseline |
The psychodynamic dimension
of resilience in 21 0.1. Children and their parents |
P
14 |
DE COSTER Peter |
Follow-up history and unusual
oral and dental features in a patient with human dermatosparaxis (ehlers-danlossyndrome
VII c) |
P
40 |
DE JONG-DE VOS VAN STEENWIJK
Teau C.E. |
Does pamidronate treatment
of severe osteogenesis imperfecta in children under three years of
age influence the age of achieving motor milestones ? |
P
15 |
DE PAEPE Anne |
Total absence of the a2(I)
chain due to a homozygous col1a2 mutation in a patient with an eds-like
phenotype |
P
13 |
DE PAEPE Anne |
Follow-up history and unusual
oral and dental features in a patient with human dermatosparaxis (ehlers-danlossyndrome
VII c) |
P
40 |
DEKENS René |
Total absence of the a2(I)
chain due to a homozygous col1a2 mutation in a patient with an eds-like
phenotype |
P
13 |
DeVILE Catherine |
Osteogenesis imperfecta
- a complex multi-system disorder requiring a multi-disciplinary approach |
P
12 |
DeVILE Catherine |
A standardised tool to measure
and describe scleral colour in osteogenesis imperfecta. |
P
59 |
DeVILE Catherine |
A survey of acute and chronic
pain in children with osteogenesis imperfecta. |
P
60 |
DeVILE Catherine |
Development of a clinical
research database on O.I. – lessons learnt along the way |
P
61 |
DeVILE Catherine |
Use of community health
services by people affected by osteogenesis imperfecta. |
P
62 |
DEVOGELAER Jean-Pierre |
Bone density and biochemical
markers |
S
04 |
DI LULLO Gloria A. |
Updated regional model of
a2(I) genotype-phenotype relationship in oi reveals alignment of lethal
clusters with proteoglycan binding regions of collagen |
P
43 |
DODIG Damir |
Our experience in bisphosphonate
therapy for osteogenesis imperfecta |
P
28 |
DORF Haia |
Osteogenesis imperfecta
and type 2 diabetes mellitus (mody) in two siblings |
P
21 |
ENGELBERT Raoul H.H. |
(Re)habilitation in children
with osteogenesis imperfecta; shifting the focus from impairment towards
(dis)ability and quality of life |
S
05 |
ENGELBERT Raoul H.H. |
Does pamidronate treatment
of severe osteogenesis imperfecta in children under three years of
age influence the age of achieving motor milestones ? |
P
15 |
ENGELBERT Raoul H.H. |
Scoliosis in children with
osteogenesis imperfecta - influence of severity of disease and age
of reaching motor milestones - |
P
16 |
ENGELBERT Raoul H.H. |
Lifespan and elongation
of the bailey-dubow nail in osteogene-sis imperfecta. |
P
29 |
ENGELBERT Raoul H.H. |
Osteogenesis imperfecta
in childhood: mr imaging of basilar impression -a follow up study- |
P
30 |
ENGELBERT Raoul H.H. |
Lack of gastrointestinal
complaints with the use of olpadronate in children with osteogenesis
imperfecta. |
P
31 |
ENGELBERT Raoul H.H. |
Osteogenesis imperfecta
in childhood: the interaction between sillence type and bmd outcome
in the deformation of vertebral bodies |
P
32 |
ENGELBERT Raoul H.H. |
Update of orthopaedic management
in osteogenesis imperfecta I due to bisphosphonates |
P
50 |
ENGELBERT Raoul H.H. |
Aerobic exercise capacity
in patients with osteogenesis imperfecta (OI) type I. |
P
55 |
